logo

Oragenics Inc. (OGEN)



Trade OGEN now with
  Date
  Headline
10/4/2021 7:34:37 AM Oragenics Awarded $250,000 Grant From NIGMS For The Continued Research And Development Of Lantibiotics
9/15/2021 7:34:35 AM Oragenics Initiates COVID-19 Challenge Study Evaluating Multiple Formulations Of SARS-CoV-2 Vaccine Candidate
8/24/2021 7:33:13 AM Oragenics Announces Postponement Of Annual Meeting Of Shareholders Due To Lack Of Quorum
5/18/2021 9:32:40 AM Oragenics Believes Existing Cash And Cash Equivalents will Fund Operating Plan Into Q3 Of 2022
5/3/2021 7:36:33 AM Alan Joslyn Resigns As CEO, President And Director Of Oragenics To Pursue Other Opportunities
3/9/2021 7:11:27 AM Oragenics Enters Material Transfer Agreement With Biodextris For Mucosal Adjuvant For Intranasal COVID-19 Vaccine
1/14/2021 7:15:33 AM Oragenics Says Optimistic That Terra CoV-2 Vaccine Will Ultimately Prove To Have Several Advantages
1/7/2021 7:17:49 AM Oragenics Enters Into Material Transfer Agreement With Adjuvance Technologies For Use Of Adjuvant TQL1055
9/28/2020 8:06:00 AM Oragenics Provides An Update On Funding For Its SARS-CoV-2 Vaccine
8/20/2020 8:33:00 AM Oragenics And Avid Bioservices Enter Process Development And drug Substance Manufacturing Agreement
7/22/2020 7:38:03 AM Oragenics: Study Shows SARS-CoV-2 Spike Protein Licensed By Company From NIH Produces Neutralizing Antibodies